131 related articles for article (PubMed ID: 18187485)
1. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer.
Santini D; Perrone G; Vincenzi B; Lai R; Cass C; Alloni R; Rabitti C; Antinori A; Vecchio F; Morini S; Magistrelli P; Coppola R; Mackey JR; Tonini G
Ann Oncol; 2008 Apr; 19(4):724-8. PubMed ID: 18187485
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
Santini D; Vincenzi B; Fratto ME; Perrone G; Lai R; Catalano V; Cass C; Ruffini PA; Spoto C; Muretto P; Rizzo S; Muda AO; Mackey JR; Russo A; Tonini G; Graziano F
J Cell Physiol; 2010 May; 223(2):384-8. PubMed ID: 20082300
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
Kawabata Y; Nishi T; Kidani A; Tajima Y
Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
[TBL] [Abstract][Full Text] [Related]
4. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
5. Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.
Perrone G; Morini S; Santini D; Rabitti C; Vincenzi B; Alloni R; Antinori A; Magistrelli P; Lai R; Cass C; Mackey JR; Coppola R; Tonini G; Onetti Muda A
Eur J Histochem; 2010; 54(3):e38. PubMed ID: 20839414
[TBL] [Abstract][Full Text] [Related]
6. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
7. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
[TBL] [Abstract][Full Text] [Related]
10. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
11. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.
Reiman T; Clarke ML; Dabbagh L; Vsianska M; Coupland RW; Belch AR; Baldwin SA; Young JD; Cass CE; Mackey JR
Leuk Lymphoma; 2002 Jul; 43(7):1435-40. PubMed ID: 12389626
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
Xiao JC; Zhang TP; Zhao YP
Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
[TBL] [Abstract][Full Text] [Related]
14. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
[TBL] [Abstract][Full Text] [Related]
15. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
Kawada N; Uehara H; Katayama K; Nakamura S; Takahashi H; Ohigashi H; Ishikawa O; Nagata S; Tomita Y
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):717-22. PubMed ID: 22426593
[TBL] [Abstract][Full Text] [Related]
16. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
[TBL] [Abstract][Full Text] [Related]
17. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
Okamura Y; Yasukawa S; Narimatsu H; Boku N; Fukutomi A; Konishi M; Morinaga S; Toyama H; Kaneoka Y; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Kainuma O; Hishinuma S; Yamaguchi R; Nagino M; Hirano S; Yanagisawa A; Mori K; Uesaka K
Cancer Sci; 2020 Feb; 111(2):548-560. PubMed ID: 31778273
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
19. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
